ETG Lublin Sp. z o.o.

Lublin 22 trials 21 recruiting

22 Registered trials

21 Currently recruiting

Organisation

ETG Lublin Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100053624

Address

Ul. Wladyslawa Kunickiego 26a, 20-412, Poland

Departments

2215; ETG Lublin
ETG Debica
ETG Dębica Poradnie Specjalistyczne
ETG Lublin
ETG Lublin Poradnie Specjalistyczne
ETG Lublin Sp
ETG Poniatowa
N/A
NA
Poradnie specjalistyczne

Clinical trials at this site (22)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1) Recruiting

2025-521315-39-00 Axial spondyloarthritis 1 2025-11-05
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting

2025-520831-18-00 Primary Sjogren’s Disease 4 2025-12-12
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with… Recruiting

2023-510369-92-00 Mixed Dyslipidemia 4 2025-01-28
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Migraine 5 2023-03-07
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting

2024-510656-13-00 Migraine 5 2022-11-08
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended

2024-519417-57-00 Thyroid eye disease 5 2025-06-25
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25